Instrument NameKura OncologyInstrument Symbol(KURA-Q)

Instrument ExchangeNASDAQ

These two healthcare growth stocks could have a lot more room to run.

We are looking for price trend-focused opportunities in U.S.-listed equities

With bullish traders anticipating a quick pop in KURA stock, outside observers need to pay attention, especially because of the underlying short position.

The second-largest cause of death in the U.S., more than 600,000 deaths from cancer will occur in 2023. Learn about the best cancer stocks to invest in now.

June S&P 500 futures (ESM23) are up +0.12%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.16% this morning as market participants braced for the Federal Reserve’s interest rate decision while also awaiting crucial U.S. PPI data.

– Recommended Phase 2 dose for ziftomenib identified, pending FDA review – – Additional 18 patients enrolled in KOMET-001 trial of ziftomenib in...

SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the...

SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the...

SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the...

– Enrollment completed in Phase 1b expansion cohorts for ziftomenib; topline data expected in third quarter, full data presentation in fourth quarter – –...

SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the...

– Late-breaking presentation at AACR demonstrates potential to significantly delay onset of drug resistance to EGFR-targeted therapies through combination...

– Presentations to highlight significant opportunities targeting farnesyl transferase inhibition –...

SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the...

– Patient enrollment continues in KOMET-001 Phase 1b study of ziftomenib (KO-539) in AML – – Multiple milestones and data readouts from KOMET-001 expected...

SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the...

SAN DIEGO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the...

– Expanded leadership team to support and advance the Company's rapid growth –...

– FDA lifts partial clinical hold following agreement on mitigation strategy for differentiation syndrome – – KOMET-001 study to resume screening and...

– Preclinical data suggest HRAS and PI3Kα are co-dependent oncogenes in HNSCC – – Combination has potential to address up to 50% of patients with HNSCC – ...

– Overall response rate of 56% and median overall survival of 32.8 months in patients with advanced AITL, an aggressive form of T-cell lymphoma – –...

– New findings presented at ASH support development strategy for KO-539 in KMT2A-rearranged and NPM1-mutant AML –...

Management to host webcast and conference call today at 8:30 a.m. ET...

SAN DIEGO, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the...